STM JOURNALS

Research & Reviews: A Journal of
Drug Formulation, Development and Production

ISSN: 2394-1944
Volume 11, Issue 2, 2024
May–August
DOI (Journal): 10.37591/RRJoDFDP

https://journals.stmjournals.com/rrjodfdp

Review RRJoDFDP

Ligand Based Drug Virtual Screening in Computer Aided Drug Design: A Review

Mohd. Wasiullah[1], Piyush Yadav[2], Mohammad Adham[3], Satish Kumar Yadav[4,*], Vikash Yadav[5]

Abstract

Computer-Aided Drug Design (CADD) has revolutionized the drug discovery process by providing efficient and cost-effective methods for identifying potential drug candidates. Within CADD, ligand-based virtual screening techniques play a pivotal role in the early stages of drug discovery. This review provides a comprehensive overview of ligand-based drug virtual screening, focusing on its principles, applications, challenges, and future directions. Fundamentals of ligand-based virtual screening, including pharmacophore-based methods, similarity searching, and machine learning approaches, are elucidated. Applications of ligand-based virtual screening in drug repurposing, lead optimization, and target identification are discussed, alongside case studies highlighting its success in identifying novel drug candidates. Furthermore, the review compares ligand-based virtual screening with structure-based approaches, emphasizing their complementary nature and integration in CADD workflows. Challenges such as data availability, model accuracy, and computational resources are addressed, with recommendations provided for best practices in virtual screening studies.

Keywords: Virtual screening, deep learning, drug discovery, drug-target interaction, drug-target affinity

INTRODUCTION

In the ever-evolving landscape of drug discovery, Computer-Aided Drug Design (CADD) stands as a cornerstone, offering innovative computational methodologies to streamline and expedite the identification of potential therapeutic agents [1]. At the heart of CADD lies virtual screening, a powerful technique that leverages computational algorithms to sift through vast chemical libraries, identifying promising candidates for further experimental validation. Within the realm of virtual screening, ligand-based approaches have emerged as indispensable tools, offering unique insights into the structure-activity relationships (SAR) of small molecule ligands and their interactions with target biomolecules (Figure 1).

***Author for Correspondence**
Satish Kumar Yadav
E-mail: slk.pharma@gmail.com

[1]Principal and Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[2]Professor and Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[3]Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[4]Associate Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
[5]Professor, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India

Received Date: May 10, 2024
Accepted Date: May 17, 2024
Published Date: July 10, 2024

Citation: Mohd. Wasiullah, Piyush Yadav, Mohammad Adham, Satish Kumar Yadav, Vikash Yadav. Ligand Based Drug Virtual Screening in Computer Aided Drug Design: A Review. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2024; 11(2): 1–8p.

The essence of ligand-based virtual screening lies in its ability to exploit the wealth of existing chemical and biological data, harnessing patterns and relationships to predict the bioactivity of novel compounds [1]. Unlike structure-based methods, which rely on detailed knowledge of target protein structures, ligand-based approaches focus on the properties and characteristics of known ligands, using them as probes to explore chemical space and

identify molecules with desired pharmacological profiles [2, 3]. This reliance on ligand information makes ligand-based virtual screening particularly well-suited for scenarios where protein structures are unknown or difficult to obtain, offering a versatile and cost-effective alternative for early-stage drug discovery [4]. This review aims to provide a comprehensive examination of ligand-based drug virtual screening within the context of CADD, exploring its fundamentals, applications, challenges, and future prospects. By delving into the underlying principles, methodologies, and real-world applications of ligand-based virtual screening, this review seeks to elucidate its pivotal role in modern drug discovery efforts [3].



Figure 1. Schematic diagram of common virtual screening methods.

FUNDAMENTALS OF LIGAND-BASED DRUG VIRTUAL SCREENING

Ligand-based drug virtual screening represents a sophisticated interplay between chemical informatics and computational biology, aimed at identifying promising drug candidates based on the properties and characteristics of known ligands [3]. This section delves into the fundamental principles that underpin ligand-based virtual screening methodologies, elucidating the diverse array of techniques and algorithms employed in this process [1].

Ligands in Drug Design

Understanding the concept of ligands is foundational to grasp the essence of ligand-based virtual screening [3]. A ligand, in the context of drug design, refers to a small molecule that binds to a target biomolecule, such as a protein, enzyme, or nucleic acid. Ligands exert their pharmacological effects by interacting with specific regions on the target, modulating its activity and function [5]. By elucidating

the structural and chemical properties of ligands, researchers can gain valuable insights into the mechanisms of ligand-target interactions, paving the way for rational drug design strategies [1].

Principles of ligand-based virtual screening

Ligand-based virtual screening operates on the premise of molecular similarity, wherein the biological activity of a compound is assumed to be correlated with its structural and physicochemical resemblance to known active compounds [3]. The key principle underlying ligand-based virtual screening is the identification of molecular descriptors or fingerprints that capture the essential features of bioactive molecules [6]. These descriptors serve as computational probes to search large chemical databases, identifying molecules with similar properties and potential pharmacological activity [7].

Methods and Algorithms in Ligand-Based Virtual Screening

Ligand-based virtual screening encompasses a diverse array of methods and algorithms, each tailored to exploit different facets of molecular similarity [8, 9]. Pharmacophore-based screening relies on the identification of common structural motifs or features shared by active ligands, serving as templates for the selection of candidate compounds [6]. Similarity searching involves the comparison of molecular fingerprints or structural descriptors to quantify the similarity between a query molecule and known active compounds [3]. Machine learning approaches, such as quantitative structure-activity relationship (QSAR) modeling, utilize statistical algorithms to correlate molecular descriptors with biological activity, enabling the prediction of compound potency and efficacy [4].

Applications of ligand-based virtual screening

This section delves into the myriad applications of ligand-based virtual screening in drug discovery, highlighting its versatility and efficacy across various stages of the drug development pipeline.

Drug Repurposing and Discovery

Ligand-based virtual screening offers a valuable strategy for drug repurposing, whereby existing drugs or compounds are repositioned for new therapeutic indications based on their shared pharmacological profiles [1]. By leveraging molecular similarity and pharmacophore-based approaches, researchers can identify novel uses for approved drugs or discontinued compounds, accelerating the development of treatments for unmet medical needs [9].

LEAD OPTIMIZATION

In the pursuit of novel drug candidates, lead optimization plays a pivotal role in refining and enhancing the pharmacological properties of initial hits or leads [10]. Ligand-based virtual screening facilitates lead optimization by guiding the selection of analogs or derivatives with improved potency, selectivity, and pharmacokinetic properties [8]. Through iterative cycles of screening and molecular modeling, researchers can iteratively refine lead compounds, optimizing their drug-like properties and efficacy [11].

Target Identification and Validation

Identifying suitable drug targets is a critical step in the drug discovery process, requiring comprehensive knowledge of target biology and disease mechanisms [9]. Ligand-based virtual screening can aid in target identification by identifying ligands with high affinity and specificity for a given target, providing valuable insights into its biological function and therapeutic potential. Moreover, ligand-based approaches can help validate potential drug targets by elucidating their relevance in disease pathways and confirming their drug ability [10].

Prediction of off-target effects

Mitigating off-target effects is a key challenge in drug development, as unintended interactions with non-target proteins can lead to adverse reactions and toxicity [12]. Ligand-based virtual screening can predict off-target effects by identifying structural similarities between candidate compounds and known

ligands for off-target proteins [13–17]. By proactively assessing potential off-target interactions, researchers can minimize the risk of adverse effects and prioritize safer drug candidates for further development [7].

Challenges and Limitations

While ligand-based virtual screening offers immense promise in accelerating the drug discovery process, it is not without its challenges and limitations. This section delves into the key obstacles that researchers may encounter when employing ligand-based virtual screening methodologies [18].

Data quality and availability

One of the primary challenges in ligand-based virtual screening is the quality and availability of data [16]. The success of virtual screening relies heavily on the availability of comprehensive and high-quality datasets comprising bioactive molecules and their associated biological activities [10]. However, the lack of standardized data formats, inconsistent data curation, and discrepancies in experimental assays can introduce biases and limitations in virtual screening studies [17].

Accuracy of Prediction Models

Another challenge lies in the accuracy and reliability of prediction models used in ligand-based virtual screening. While machine learning algorithms and quantitative structure-activity relationship (QSAR) models offer powerful tools for predicting compound bioactivity, their performance is contingent upon the quality and relevance of input features, as well as the robustness of training datasets [15]. Moreover, the extrapolation of prediction models to novel chemical scaffolds or target classes may be limited by the scope and diversity of training data, leading to potential biases and inaccuracies [13].

INTERPRETATION OF RESULTS

Interpreting the results of ligand-based virtual screening studies can be challenging due to the complexity of molecular interactions and the inherent limitations of computational models [17]. While virtual screening algorithms can identify candidate compounds with high predicted affinity for a target of interest, validating these predictions experimentally remains a formidable task. Researchers must exercise caution when interpreting virtual screening results, considering factors such as compound promiscuity, target selectivity, and potential off-target effects [16].

Computational Resources and Time Constraints

Ligand-based virtual screening often requires substantial computational resources and time, particularly when screening large chemical libraries or performing extensive molecular dynamics simulations [18]. The scalability and efficiency of virtual screening algorithms may be limited by computational constraints, hindering the exploration of chemical space and the identification of truly promising drug candidates. Moreover, the rapid pace of technological advancements in computing hardware and software necessitates ongoing optimization and adaptation of virtual screening workflows to remain competitive [14].

Addressing these challenges

Despite these challenges, researchers can adopt several strategies to mitigate the limitations of ligand-based virtual screening. Enhancing data quality and curation efforts, leveraging diverse data sources and collaborative networks, and embracing advances in machine learning and artificial intelligence are crucial steps towards improving the reliability and effectiveness of virtual screening methodologies [19]. Moreover, integrating ligand-based approaches with complementary computational and experimental techniques can enhance the robustness and confidence of drug discovery efforts, ultimately advancing the development of novel therapeutic agents [11].

CASE STUDIES AND SUCCESS STORIES

This section provides a detailed exploration of case studies and success stories that exemplify the practical application and effectiveness of ligand-based virtual screening in drug discovery [20].

Case Study 1: Drug Repurposing for COVID-19 Treatment

This case study examines how ligand-based virtual screening was utilized to repurpose existing drugs for the treatment of COVID-19. By identifying compounds with structural similarity to known antiviral agents and targeting key viral proteins, researchers successfully identified several promising candidates for clinical evaluation, expediting the search for effective therapeutics against the global pandemic [19, 20].

Case Study 2: Lead Optimization in Oncology

In this case study, ligand-based virtual screening was employed to optimize lead compounds for the treatment of cancer. Through iterative rounds of screening and molecular modeling, researchers identified analogs with improved potency, selectivity, and pharmacokinetic properties, leading to the development of novel anticancer agents with enhanced therapeutic potential and reduced toxicity [18].

Case Study 3: Target Identification and Validation in Neurodegenerative Diseases

This case study focuses on the application of ligand-based virtual screening in target identification and validation for neurodegenerative diseases [20]. By analyzing ligand-target interactions and exploring chemical space, researchers identified potential drug targets implicated in disease pathways, providing valuable insights into disease mechanisms and facilitating the development of targeted therapeutics for Alzheimer's and Parkinson's diseases [7].

Case Study 4: Prediction of Off-Target Effects in Cardiotoxicity

In this case study, ligand-based virtual screening was employed to predict off-target effects and mitigate cardiotoxicity in drug development. By screening candidate compounds against a panel of known cardiac ion channels and receptors, researchers identified potential liabilities and optimized lead compounds to minimize the risk of adverse cardiac events, demonstrating the utility of virtual screening in safety assessment and risk mitigation strategies [19].

ANALYSIS AND IMPLICATIONS

Through a comprehensive analysis of these case studies and success stories, this section highlights the versatility, efficacy, and real-world impact of ligand-based virtual screening in drug discovery [21, 22]. By elucidating the underlying strategies, methodologies, and outcomes of these studies, researchers can glean valuable insights and best practices for incorporating ligand-based virtual screening into their own drug discovery workflows, ultimately accelerating the development of new therapeutic agents for a wide range of diseases and conditions [19].

COMPARISON WITH STRUCTURE-BASED VIRTUAL SCREENING

This section provides a comparative analysis of ligand-based virtual screening with structure-based approaches, highlighting their respective strengths, weaknesses, and complementary roles in computer-aided drug design (CADD) (Figure 2) [23].

PRINCIPLES AND METHODOLOGIES

Here, the fundamental principles and methodologies of both ligand-based and structure-based virtual screening are elucidated [22]. Ligand-based approaches rely on molecular similarity and ligand-target interactions, whereas structure-based methods utilize detailed knowledge of target protein structures and binding sites [21]. The differences in computational strategies and input data requirements are discussed, providing insights into the distinct workflows and applications of each approach [22].

Advantages of Ligand-Based Virtual Screening

This subsection outlines the advantages of ligand-based virtual screening over structure-based methods [19]. Ligand-based approaches are particularly well-suited for scenarios where target protein structures are unknown or difficult to obtain [22]. They offer versatility, scalability, and efficiency in screening large chemical libraries, making them ideal for lead identification and optimization in early-stage drug discovery [20].



Figure 2. General VS workflow.

Advantages of Structure-based Virtual Screening

Conversely, this subsection highlights the unique advantages of structure-based virtual screening [22]. Structure-based methods enable the exploration of ligand-protein interactions at the atomic level, facilitating the rational design of ligands with precise binding modes and affinities. They are especially effective for targets with well-characterized structures and binding sites, allowing for structure-guided optimization and rational drug design [19].

Complementary Nature and Integration

The complementary nature of ligand-based and structure-based virtual screening is emphasized in this section. While each approach has its strengths and limitations, they can be synergistically integrated to enhance the efficiency and effectiveness of CADD workflows [23]. By combining ligand-based and structure-based methods, researchers can leverage the advantages of both approaches, mitigating their respective weaknesses and maximizing the likelihood of identifying successful drug candidates [18].

CONCLUSION

In conclusion, this review has provided a comprehensive examination of ligand-based drug virtual screening within the context of Computer-Aided Drug Design (CADD). We have explored the fundamental principles, diverse applications, challenges, and future directions of ligand-based virtual screening methodologies, highlighting its pivotal role in modern drug discovery efforts. Throughout this review, we have underscored the importance of ligand-based virtual screening as a powerful and versatile tool for identifying potential drug candidates. By leveraging molecular similarity and ligand-target interactions, ligand-based approaches offer efficient and cost-effective solutions for lead identification, optimization, and target validation across various therapeutic areas and target classes. Despite its many advantages, ligand-based virtual screening is not without its challenges and limitations. Issues such as data quality, accuracy of prediction models, interpretation of results, and

computational resources require careful consideration and mitigation strategies to ensure the reliability and reproducibility of screening studies.

Summary of Key Points

We recapitulate the main points discussed in the review, including the principles of ligand-based virtual screening, its applications across various stages of the drug discovery pipeline, challenges and limitations, and emerging trends in methodology and technology.

Importance of Ligand-Based Virtual Screening

We underscore the importance of ligand-based virtual screening as a versatile and efficient tool for identifying potential drug candidates, particularly in scenarios where target protein structures are unavailable or difficult to obtain. We highlight its role in accelerating the drug discovery process, reducing costs, and mitigating risks associated with traditional experimental approaches.

Future Directions and Opportunities

We discuss the future directions and opportunities for advancing ligand-based virtual screening methodologies, including the integration of machine learning techniques, utilization of big data analytics, and potential impact of quantum computing. We emphasize the need for continued innovation, collaboration, and interdisciplinary research to address existing challenges and unlock new opportunities in drug discovery.

REFERENCES

1. Salazar DE, Gormley G. Modern drug discovery and development. CTS-Clin Transl Sci. Academic Press; London U K. 2017; 719–743.
2. Berdigaliyev N, Aljofan M. An overview of drug discovery and development. Future Med Chem. 2020; 12(10): 939–947.
3. Butkiewicz M, Wang Y, Bryant SH, Lowe Jr EW, Weaver DC, Meiler J. High-throughput screening assay datasets from the pubchem database. Chem Inform (Wilmington, Del.). 2017; 3(1): 1.
4. Scior T, Bender A, Tresadern G, *et al.* Recognizing pitfalls in virtual screening: A critical review. J Chem Inf Model. 2012; 52(4): 867–881.
5. Wang H, Tang JJ, Ding YJ, *et al.* Exploring associations of non-coding RNAs in human diseases via three-matrix factorization with hypergraph-regular terms on center kernel alignment. Brief Bioinform. 2021; 22(5): bbaa409.
6. Ezzat A, Wu M, Li X L, *et al*. Computational prediction of drug–target interactions using chemogenomic approaches: An empirical survey. Brief Bioinform. 2019; 20(4): 1337–1357.
7. Bagherian M, Sabeti E, Wang K, *et al*. Machine learning approaches and databases for prediction of drug–target interaction: A survey paper. Brief Bioinform. 2021; 22(1): 247–269.
8. Dhakal A, McKay C, Tanner JJ, *et al*. Artificial intelligence in the prediction of protein–ligand interactions: Recent advances and future directions. Brief Bioinform. 2022; 23(1): bbab476.
9. Agamah FE, Mazandu GK, Hassan R, *et al*. Computational/in silico methods in drug target and lead prediction. Brief Bioinform. 2020; 21(5): 1663–1675.
10. Abbasi K, Razzaghi P, Poso A, *et al*. Deep learning in drug target interaction prediction: Current and future perspectives. Curr Med Chem. 2021; 28(11): 2100–2113.
11. Hughes JP, Rees SS, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011; 162(6): 1239–1249.
12. Carnero A. High throughput screening in drug discovery. Clin Transl Oncol. 2006 Jul; 8(7): 482–90.
13. Introduction to pharmacokinetics and pharmacodynamics. In: Spruill WJ, Wade WE, DiPiro JT, Blouin RA, Pruemer JM, editors. Concepts in Clinical Pharmacokinetics. 6th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2014. p. 1–18.
14. Guedes R, Serra P, Salvador J, Guedes R. Computational approaches for the discovery of human proteasome inhibitors: an overview. Molecules. 2016; 21(7): 927.

15. Petterson I, Balle T, Liljefors T. Textbook of Drug Design and Discovery. 5th ed. Boca Raton (FL): CRC Press, Taylor & Francis Group; 2010. p. 43–57.
16. Kubinyi H. Quantitative structure--activity relationships. The bilinear model, a new model for nonlinear dependence of biological activity on hydrophobic character. J Med Chem. 1977 May; 20(5): 625–9. doi: 10.1021/jm00215a002
17. Polanski J. Receptor dependent multidimensional QSAR for modeling drug – receptor interactions. Curr Med Chem. 2009; 16(25): 3243–3257.
18. Sippl W. 3D-QSAR - Applications, recent advances, and limitations. In: Recent Advances in QSAR Studies: Challenges and Advances in Computational Chemistry and Physics. Dordrecht: Springer; 2010; 103–126.
19. Yun T, Weiliang Z, Kaixian C, Hualiang J. New technologies in computer-aided drug design: Toward target identification and new chemical entity discovery. Drug Discov Today Technol. 2006; 3(3): 307–313.
20. Pranita PK, Madhavi MM, Rishikesh VA, Rajesh JO, Sandip SK. Computer-aided drug design: an innovative tool for modeling. J Med Chem. 2012; 2(4): 139–148.
21. Pugazhendhi D, Umamaheswari TS. In silico methods in drug discovery–a review. Int J Adv Res Comput Sci Softw Eng. 2013; 3(5): 680–683.
22. Adam Shahul Hameed. (2015 May 20). Structure-based drug design (Docking and de novo drug design). [Online]. Anna University Chennai. http://www.slideshare.net/adammbbs/structure-based-drug-design-48389641/12.
23. Silvana G. Computer-based methods of inhibitor prediction. Chapter 3. In: An Integrated View of the Molecular Recognition and Toxinology - From Analytical Procedures to Biomedical Applications. Intech open science and open minds. 2013; 73–90.

